DK4116301T3 - Fusioneret tricyklisk forbindelse og medicinsk anvendelse heraf - Google Patents
Fusioneret tricyklisk forbindelse og medicinsk anvendelse herafInfo
- Publication number
- DK4116301T3 DK4116301T3 DK21764169.5T DK21764169T DK4116301T3 DK 4116301 T3 DK4116301 T3 DK 4116301T3 DK 21764169 T DK21764169 T DK 21764169T DK 4116301 T3 DK4116301 T3 DK 4116301T3
- Authority
- DK
- Denmark
- Prior art keywords
- medical use
- tricyclic compound
- fused tricyclic
- fused
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11002—[Pyruvate dehydrogenase (acetyl-transferring)] kinase (2.7.11.2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020036931 | 2020-03-04 | ||
| JP2021001452 | 2021-01-07 | ||
| PCT/JP2021/008055 WO2021177330A1 (ja) | 2020-03-04 | 2021-03-03 | 縮合三環性化合物及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4116301T3 true DK4116301T3 (da) | 2025-10-20 |
Family
ID=77613417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21764169.5T DK4116301T3 (da) | 2020-03-04 | 2021-03-03 | Fusioneret tricyklisk forbindelse og medicinsk anvendelse heraf |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20230025880A1 (enExample) |
| EP (2) | EP4116301B1 (enExample) |
| JP (2) | JP7739012B2 (enExample) |
| KR (1) | KR20220149688A (enExample) |
| CN (1) | CN115151543B (enExample) |
| AU (1) | AU2021230880A1 (enExample) |
| BR (1) | BR112022014749A2 (enExample) |
| CA (1) | CA3166747A1 (enExample) |
| CL (1) | CL2022002355A1 (enExample) |
| CO (1) | CO2022012548A2 (enExample) |
| DK (1) | DK4116301T3 (enExample) |
| FI (1) | FI4116301T3 (enExample) |
| HR (1) | HRP20251364T1 (enExample) |
| IL (1) | IL295836B1 (enExample) |
| LT (1) | LT4116301T (enExample) |
| MX (1) | MX2022010950A (enExample) |
| PE (1) | PE20221908A1 (enExample) |
| PH (1) | PH12022552259A1 (enExample) |
| PT (1) | PT4116301T (enExample) |
| TW (1) | TWI884224B (enExample) |
| WO (1) | WO2021177330A1 (enExample) |
| ZA (1) | ZA202209620B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019214048B2 (en) * | 2018-02-01 | 2023-03-16 | Japan Tobacco Inc. | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes |
| CN115151543B (zh) * | 2020-03-04 | 2024-12-17 | 日本烟草产业株式会社 | 稠合三环化合物及其医药用途 |
| MX2024002705A (es) * | 2021-09-01 | 2024-03-20 | Japan Tobacco Inc | Compuesto triciclico que contiene nitrogeno y su uso farmaceutico. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004089380A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Pharmaceutical use of fused 1,2,4-triazoles |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| KR100808551B1 (ko) * | 2006-12-01 | 2008-03-03 | 한국생명공학연구원 | 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| ES2663789T3 (es) * | 2013-03-15 | 2018-04-17 | Japan Tobacco, Inc. | Compuesto de pirazol-amida y usos medicinales del mismo |
| JP6847942B2 (ja) | 2015-07-31 | 2021-03-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 二環式複素環式誘導体 |
| AU2019214048B2 (en) * | 2018-02-01 | 2023-03-16 | Japan Tobacco Inc. | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes |
| WO2020054734A1 (ja) | 2018-09-11 | 2020-03-19 | 日本たばこ産業株式会社 | ピラゾール-アミド化合物を含有する慢性腎臓病の治療又は予防剤 |
| CN115151543B (zh) | 2020-03-04 | 2024-12-17 | 日本烟草产业株式会社 | 稠合三环化合物及其医药用途 |
-
2021
- 2021-03-03 CN CN202180018517.1A patent/CN115151543B/zh active Active
- 2021-03-03 DK DK21764169.5T patent/DK4116301T3/da active
- 2021-03-03 LT LTEPPCT/JP2021/008055T patent/LT4116301T/lt unknown
- 2021-03-03 EP EP21764169.5A patent/EP4116301B1/en active Active
- 2021-03-03 WO PCT/JP2021/008055 patent/WO2021177330A1/ja not_active Ceased
- 2021-03-03 IL IL295836A patent/IL295836B1/en unknown
- 2021-03-03 US US17/602,103 patent/US20230025880A1/en active Pending
- 2021-03-03 MX MX2022010950A patent/MX2022010950A/es unknown
- 2021-03-03 PE PE2022001891A patent/PE20221908A1/es unknown
- 2021-03-03 FI FIEP21764169.5T patent/FI4116301T3/fi active
- 2021-03-03 AU AU2021230880A patent/AU2021230880A1/en active Pending
- 2021-03-03 JP JP2021033150A patent/JP7739012B2/ja active Active
- 2021-03-03 PT PT217641695T patent/PT4116301T/pt unknown
- 2021-03-03 KR KR1020227032125A patent/KR20220149688A/ko active Pending
- 2021-03-03 TW TW110107548A patent/TWI884224B/zh active
- 2021-03-03 EP EP25206111.4A patent/EP4663189A2/en active Pending
- 2021-03-03 BR BR112022014749A patent/BR112022014749A2/pt unknown
- 2021-03-03 HR HRP20251364TT patent/HRP20251364T1/hr unknown
- 2021-03-03 CA CA3166747A patent/CA3166747A1/en active Pending
- 2021-03-03 PH PH1/2022/552259A patent/PH12022552259A1/en unknown
-
2022
- 2022-08-29 ZA ZA2022/09620A patent/ZA202209620B/en unknown
- 2022-08-29 CL CL2022002355A patent/CL2022002355A1/es unknown
- 2022-09-01 CO CONC2022/0012548A patent/CO2022012548A2/es unknown
-
2025
- 2025-09-03 JP JP2025145992A patent/JP2025175000A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022010950A (es) | 2022-10-07 |
| CN115151543A (zh) | 2022-10-04 |
| WO2021177330A1 (ja) | 2021-09-10 |
| KR20220149688A (ko) | 2022-11-08 |
| JP7739012B2 (ja) | 2025-09-16 |
| CA3166747A1 (en) | 2021-09-10 |
| JP2025175000A (ja) | 2025-11-28 |
| US20230025880A1 (en) | 2023-01-26 |
| EP4116301A1 (en) | 2023-01-11 |
| HRP20251364T1 (hr) | 2025-12-19 |
| AU2021230880A1 (en) | 2022-09-29 |
| CN115151543B (zh) | 2024-12-17 |
| PH12022552259A1 (en) | 2023-11-20 |
| TWI884224B (zh) | 2025-05-21 |
| JP2022007994A (ja) | 2022-01-13 |
| ZA202209620B (en) | 2023-12-20 |
| IL295836A (en) | 2022-10-01 |
| CL2022002355A1 (es) | 2023-03-03 |
| EP4116301B1 (en) | 2025-10-08 |
| EP4116301A4 (en) | 2024-04-03 |
| PT4116301T (pt) | 2025-11-12 |
| IL295836B1 (en) | 2025-09-01 |
| PE20221908A1 (es) | 2022-12-23 |
| EP4663189A2 (en) | 2025-12-17 |
| BR112022014749A2 (pt) | 2022-10-11 |
| LT4116301T (lt) | 2025-11-10 |
| FI4116301T3 (fi) | 2025-12-19 |
| TW202146410A (zh) | 2021-12-16 |
| CO2022012548A2 (es) | 2022-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3917616T3 (da) | Heterocykliske forbindelser og anvendelse deraf | |
| DK3938047T3 (da) | Broforbundne tricykliske carbamoylpyridonforbindelser og deres farmaceutiske anvendelse | |
| DK3946464T3 (da) | Forbindelser og konjugater deraf | |
| IL285178A (en) | Compounds and uses thereof | |
| DK4161935T3 (da) | Brm-målrettende forbindelser og tilhørende anvendelsesmetoder | |
| IL277640A (en) | Humanized bcma antibody and bcma-car-t cells | |
| DK4305034T3 (da) | Brodannede tricykliske carbamoylpyridonforbindelser og anvendelse heraf | |
| DK4116301T3 (da) | Fusioneret tricyklisk forbindelse og medicinsk anvendelse heraf | |
| DK3947375T3 (da) | Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf | |
| DK4196479T5 (da) | Substituerede pyridotriazinforbindelser og anvendelser deraf | |
| EP4338711A4 (en) | Medical stent | |
| DK3765525T5 (da) | Biparatopiske anti-her2-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder | |
| IL283787A (en) | Herboxidiene antibody-drug conjugates and methods of use | |
| DK3710485T3 (da) | Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder | |
| DK3892621T3 (da) | Haloallylaminforbindelser og anvendelse deraf | |
| EP4273146A4 (en) | TRICYCLIC COMPOUND AND ITS USE | |
| DK3919498T6 (da) | Pyrrolopyrimidinderivat og anvendelse deraf | |
| EP3854293A4 (en) | ENDOSCOPE TUBE AND ENDOSCOPE | |
| DK4125842T3 (da) | Samtidig indgivelse af mirdametinib og lifirafenib til anvendelse til behandling af kræftformer | |
| EP4159104A4 (en) | MEDICAL CAPSULE | |
| DK4299569T3 (da) | Fusioneret polycyklisk substitueret 5-carboxylsyre-thienopyrimidindionforbindelse og anvendelse deraf | |
| DK3932909T3 (da) | Benzoindazolonforbindelse og mellemprodukt heraf | |
| DK3867244T3 (da) | 4-pyrazin-2-ylmethylmorfolinderivater og anvendelse deraf som lægemiddel | |
| IL313144A (en) | Carboline compounds and use thereof | |
| EP4438040A4 (en) | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND ITS PHARMACEUTICAL USE |